Carregant...
Risankizumab in the treatment of psoriasis – literature review
Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism o...
Guardat en:
| Publicat a: | Reumatologia |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710847/ https://ncbi.nlm.nih.gov/pubmed/31462831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/reum.2019.86426 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|